サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1136909

メタボロミクスの世界市場-2022-2029

Global Metabolomics Market - 2022-2029
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
メタボロミクスの世界市場-2022-2029
出版日: 2022年10月13日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場力学

メタボロミクス市場の成長は、研究開発費の増加、標的治療の普及、技術の進歩、医療費および研究開発費の増加、臨床応用技術の採用の増加によってもたらされます。

研究開発費の増加が市場成長の原動力となる見通し

民間および政府組織による研究開発への資金提供の増加は、予測期間中に市場を押し上げると予想されます。たとえば、カナダ革新財団の主要科学イニシアティブファンドは、メタボロミクス革新センター（TMIC）に887万9183ドル、グライコネット統合サービス（GIS）に106万4968ドルを提供し、これらのセンターがグリコミクスやメタボロミクスなどの先駆的研究を継続できるように支援しています。

さらに、市場プレイヤーは、買収、コラボレーション、製品発売などの市場戦略を採用しています。例えば、2020年、ダナハーコーポレーションは、GEヘルスケアのライフサイエンス事業を買収しました。また、2020年には、アジレントとサーモフィッシャーが、サーモフィッシャーの分析システムとアジレントのOpenLAbクロマトグラフィーデータシステムの互換性を強化する契約を延長しました。

2020年、ウォーターズコーポレーションは、ケンブリッジのケンダル・スクエアの中心部に研究施設「Immerse Cambridge」を開設すると発表しました。地域の戦略的・協力的な場であるImmerse Cambridgeにより、ウォーターズはアカデミアや研究と連携し、次の科学的発見を加速させることを目指します。また、2020年には日立ハイテクノロジーズ億の残りの株式を取得し、子会社化しました。この子会社は、計測・分析機器の製造、チップ製造装置や産業用材料・システムの開発を担当する予定です。

データの複雑さが市場の伸びを阻害する

しかし、低分子の代謝物は化学的に多様であるため、1つの分析手法でメタボローム全体を分析することはできないです。そのため、物理的な保管、正確かつ徹底した解析、可視化のための適切なソフトウェア／データベースへの要求が高まっています。また、得られるデータもより複雑になっています。したがって、ライフサイエンス研究中に生成されるデータの複雑さとその取り扱いに関連する課題が、メタボロミクス市場の発展を抑制することが予想されます。

COVID-19の影響分析

COVID-19の登場は、世界のメタボロミクス市場にかなりの影響を与えました。2022年1月にScientific Reportsに掲載された記事によると、メタボロミクス研究の中には核磁気共鳴（NMR）を用いたものもあるが、質量分析（MS）ベースのメタボロミクスはCOVID-19疾患における見込み診断バイオマーカー候補の特定に選ばれた手法です。メタボロミクスは、COVID-19病に関連するさまざまなトピックを扱うために使用されています。例えば、メタボロミクスは、回復期の非重症COVID-19患者における性特異的代謝シフトを示し、血漿代謝の主要な変化が、男性では脂肪酸、男女ではグリセロホスホコリンと炭水化物であることを実証しています。メタボロミクスによって示されたように、肺機能が低下したCOVID-19生存者の血漿代謝物プロファイルは、健康なドナーや肺機能が正常な人のものと区別できる可能性があります。

また、パンデミック時には、主要なプレイヤーが研究活動に取り組んでいます。例えば、2020年12月には、ブルカー株式会社が開発したThe FluoroType SARS-CoV-2/Flu/RSV winter 4-plex PCR panelにより、SARS-CoV-2ウイルス、インフルエンザウイルスAおよびB、呼吸器合胞体ウイルス（RSV）を高感度で同時に検出することができます。

また、2020年7月には、ブルカー株式会社より、呼吸器・全身疾患COVID-19の原因であるSARS-CoV-2ウイルスを高精度に同定する「The FluoroType SARS-CoV-2 plus next-generation 6-plex PCR assay」が発売されています。

世界のメタボロミクス市場レポートでは、約60以上の市場データ表、55以上の図、200以上（概算）のページの構成で提供しています。

目次

第1章 市場調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

  • 市場影響要因
    • 促進要因
      • 技術的進歩
      • メタボロミクス治療の需要拡大
    • 抑制要因
      • メタボロミクス機器の高コスト
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 規制分析
  • プライシング分析
  • アンメットニーズ分析

第6章 COVID-19分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、あるいは将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 製品・サービス別

  • 分離技術
    • クロマトグラフィー
    • 液体クロマトグラフィー
    • ガスクロマトグラフィー
    • キャピラリー電気泳動
  • 検出技術
    • 核磁気共鳴分光法
    • 質量分析
    • その他
  • バイオインフォマティクスツールとサービス

第8章 アプリケーション別

  • ニュートリゲノミクス
  • バイオマーカー・創薬
  • トキシコロジー検査
  • 個別化医療
  • その他

第9章 適応症別

  • 癌
  • 神経疾患
  • 先天性代謝異常症
  • 循環器系疾患
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 治療タイプ別ベンチマーク

第12章 企業プロファイル

  • Thermo Fisher Scientific Inc.
    • 企業概要
    • 治療タイプのポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Bio-Rad Laboratories
  • Agilent Technologies Inc.
  • Danaher Corporation
  • Waters Corporation
  • Bruker Corporation
  • Human Metabolome Technologies, Inc.
  • Metabolon Inc.
  • LECO Corporation
  • Shimadzu Corporation

第13章 メタボロミクスの世界市場-DataM

目次
Product Code: DMMD448

Market Overview

Metabolomics Market was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 11.2% during the forecast period (2022-2029).

In metabolomics, biological metabolites are identified and quantified using sophisticated analytical techniques, and information is extracted and interpreted using statistical and multivariate approaches. LC-MS/MS, GC-MS, and/or NMR are some of the complimentary analytical techniques used in metabolomics to identify and quantify as many known and unidentified metabolites as possible.

Market Dynamics

The metabolomics market growth is driven by the rising funding in research and development, rising adoption of targeted therapies, technological advamcement, increasing healthcare and R&D expenditure, rise in adoption of technology for clinical applications.

The rising funding for reserch and development is expected to drive the market growth

The rising funding for research and development from private and government organizations is expected to boost the market over the forecast period. For instance, the Canadian Foundation for Innovation's Major Science Initiatives Fund has provided $8,879,183 to The Metabolomics Innovation Centre (TMIC) and $10,684,968 to GlycoNet Integrated Services (GIS), helping these centers to continue their pioneering research, including glycomics and metabolomics.

In addition, the market players are adopting market strategies, including acquisition, collaboration and product launches. For instance, in 2020, Danaher Corporation acquired GE Healthcare's Life Sciences business. Also, In 2020, Agilent and Thermo Fisher extended their agreement to enhance the compatibility of Thermo Fisher's analytical systems with Agilent's OpenLAb Chromatography Data System.

In 2020, Waters Corporation announced the opening of Immerse Cambridge, a research facility in the center of Kendall Square in Cambridge. The community's strategic, collaborative venue, Immerse Cambridge, will allow Waters to work with academia and research to accelerate the next round of scientific discoveries. Also, in 2020, Hitachi acquired the remaining shares of Hitachi High-Technologies billion and made it is subsidiary. This subsidiary will be responsible for manufacturing measuring and analytical equipment, along with developing chipmaking equipment and industrial materials and systems.

The complexity of the data will hamper the growth of the market

However, no one analytical method can be used to analyze the full metabolome due to the chemical diversity of small molecule metabolites. Therefore, there is an increased demand for physical storage, accurate and thorough analysis, and appropriate software/databases for visualization. The resulting data is also more complicated. Therefore, it is anticipated that the complexity of the data produced during life science research and the challenges associated with handling it will restrain the development of the metabolomics market.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global metabolomics market. As per the article published in Scientific Reports in January 2022, While some metabolomics studies have used nuclear magnetic resonance (NMR), mass spectrometry (MS)-based metabolomics has been the method of choice for identifying prospective diagnostic biomarker candidates in COVID-19 disease. Metabolomics has been used to address various topics related to COVID-19 disease. For example, metabolomics has shown sex-specific metabolic shifts in non-severe COVID-19 patients during recovery, demonstrating that the major plasma metabolic changes were fatty acids in men and glycerophosphocholines and carbohydrates in men and women. As demonstrated by metabolomics, plasma metabolite profiles of COVID-19 survivors with impaired pulmonary function may be distinguished from those of healthy donors or those with normal pulmonary function.

In addition, the key players are engaged in research activities during the pandemic. For instance, in December 2020, The FluoroType SARS-CoV-2/Flu/RSV winter four-plex PCR panel, developed by Bruker Corporation, allows for the sensitive and simultaneous detection of the SARS-CoV-2 virus, influenza viruses A and B, as well as the respiratory syncytial virus (RSV)

Also, in July 2020, The FluoroType SARS-CoV-2 plus next-generation 6-plex PCR assay was introduced by Bruker Corporation to precisely identify the SARS-CoV-2 virus, which is responsible for the respiratory and systemic illness COVID-19.

Segment Analysis

The separation technique segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The separation technique segment is expected to boost the market throughout the forecast. As per the article published in Novel Approaches in Drug Designing & Development in August 2021, the analytical technique of liquid chromatography is used to isolate the target analyte from the mixture. To effectively separate molecules of interest, liquid chromatography uses a liquid as the mobile phase and a solid as the stationary phase. Mass spectroscopy is performed to determine the molecular mass of the sample of interest. By measuring the sample ion's mass to charge ratio, the molecule's mass is ascertained. Due to its selectivity, low sample volume requirements, sensitivity, and speed, the combination of liquid chromatography and mass spectrometry (LC-MS) is a potent instrument with several applications. LC is now compatible with MS due to creative and fruitful research over the past few years on constructing a potential interface link between the two. In the preclinical development stage, LC-MS detects impurities, degradants, and metabolites. In addition, the use of LC-MS/MS for protein quantification has attracted much attention. It is employed in the detection of biomarkers.

Geographical Analysis

North America region holds the largest market share of the global Metabolomics market

North America dominates the metabolomics market and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2022-2029) owing to government initiatives, growth and development research activities in metabolomics, and an increase in the adoption of metabolomics in precision medicine.

The primary aim of the Metabolomics Association of North America (MANA) is to advance the field of metabolomics, particularly in North America; to give North American researchers in metabolomics sciences and related fields the chance to network; to facilitate connections between academia and industry; to provide venues for the presentation of research findings and for workshops, and to encourage the publication of metabolomics research.

In addition, in April 2020, Gilead Sciences, Inc., and Second Genome, entered into a four-year strategic collaboration to find potential new targets and drug candidates for the treatment of inflammatory bowel disease as well as to identify biomarkers linked to clinical response in up to five of Gilead's pipeline compounds for the treatment of fibrosis, inflammation, and other diseases (IBD).

Competitive Landscape

The metabolomics market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Agilent Technologies Inc., Danaher Corporation, Waters Corporation, Bruker Corporation, Human Metabolome Technologies, Inc., Metabolon Inc., LECO Corporation, and Shimadzu Corporation among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, contributing to the growth of the global metabolomics market.

For instance,

  • In June 2021, Bruker Corporation launched the FluoroType SARS-CoV-2 varied Q assay, a quantitative Liquid Array mid-plexPCR panel. This novel assay panel also detects several important mutations, enabling laboratories and hospitals to differentiate many major viral variants routinely on all positive samples. The assay achieved a sensitivity of 98% and a specificity of 100% during its clinical performance evaluation study.
  • In June 2021, at Bruker's virtual 4D-Proteomics eXceed Symposium (eXceed Symposia 2021 | Bruker), Bruker Corporation launched the two new Tim stop instruments. In addition, they advance and enable new applications and methods in unbiased proteomics/PTM characterization and unbiased, deep multi-omic biomarker discovery, for example, in cancer liquid biopsy research.

Thermo Fisher Scientific Inc

Overview:

Thermo Fisher Scientific Inc. is an American company founded in 1956 and headquartered in the United States. It provides solutions including chromatographic separations such as GC, LC and IC. It produces novel, stringent and reproducible results for high-impact discoveries.

Treatment type Portfolio:

Orbitrap Exploris GC 240: Thermo Scientific Orbitrap Exploris GC 240 mass spectrometer facilitates the most difficult analytical challenges. It delivers uncompromising qualitative and quantitative information and provides the need for research laboratories for compound identification and quantitation, including discovery profiling, metabolomics, industry research and applied quantification analyses, to gain unparalleled access to information-rich data with ease.

The global metabolomics market report would provide access to approximately 60+ market data tables, 55+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Technological advancements
      • 4.1.1.2. Rising demand for metabolomics therapy
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of metabolomics instruments
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product and Services

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 7.1.2. Market Attractiveness Index, By Product and Services
  • 7.2. Separation Techniques*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Chromatography
    • 7.2.4. Liquid Chromatography
    • 7.2.5. Gas Chromatography
    • 7.2.6. Capillary Electrophoresis
  • 7.3. Detection Techniques
    • 7.3.1. Nuclear Magnetic Resonance Spectroscopy
    • 7.3.2. Mass Spectrometry
    • 7.3.3. Others
  • 7.4. Bioinformatics Tools and Services

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Nutrigenomics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Biomarker & Drug Discovery
  • 8.4. Toxicology Testing
  • 8.5. Personalized Medicine
  • 8.6. Others

9. By Indication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.1.2. Market Attractiveness Index, By Indication
  • 9.2. Cancer*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Neurological Disorders
  • 9.4. Inborn Errors of Metabolism
  • 9.5. Cardiovascular Disorders
  • 9.6. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Vaccines Types
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. Australia
      • 10.5.7.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product and Services
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Treatment type Benchmarking

12. Company Profiles

  • 12.1. Thermo Fisher Scientific Inc.*
    • 12.1.1. Company Overview
    • 12.1.2. Treatment type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Bio-Rad Laboratories
  • 12.3. Agilent Technologies Inc.
  • 12.4. Danaher Corporation
  • 12.5. Waters Corporation
  • 12.6. Bruker Corporation
  • 12.7. Human Metabolome Technologies, Inc.
  • 12.8. Metabolon Inc.
  • 12.9. LECO Corporation
  • 12.10. Shimadzu Corporation

LIST NOT EXHAUSTIVE

13. Global Metabolomics market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us